Residual DNA Testing Companies

The global residual DNA testing market is projected to reach USD 0.37 billion by 2030 from USD 0.28 billion in 2025, at a CAGR of 6.0% during the forecast period.

The global residual DNA testing market is a competitive, featuring companies such as Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Eurofins Scientific (Luxembourg), Charles River Laboratories (US), Bio-Rad Laboratories (US), QIAGEN (Germany), F. Hoffmann-La Roche Ltd (Switzerland), Maravai LifeSciences (US), FUJIFILM Corporation (Japan), SGS Société Générale de Surveillance SA (Switzerland), Jiangsu Hillgene Biopharma Co., Ltd. (China), Revvity (US), Intertek Group plc (UK), WuXi AppTec (China), Sartorius AG (Germany), and Lonza (Switzerland). These market players have implemented several strategies, including product launches, acquisitions, agreements, collaborations, and expansions, to enhance their positions in the market.

To know about the assumptions considered for the study download the pdf brochure

Thermo Fisher Scientific Inc. (US) has emerged as one of the leading players in the residual DNA testing market as of 2024. The company’s significant market share can be attributed to its robust portfolio of products and services, which includes advanced PCR (Polymerase Chain Reaction) systems, comprehensive software solutions, and specialized detection and quantitation kits. Additionally, Thermo Fisher offers validation and implementation services designed to ensure the effective deployment of these technologies in various applications. To further cement its position in this competitive landscape, Thermo Fisher actively pursues a blend of organic and inorganic growth strategies. A notable example of this is the inauguration of its Advanced Therapies Collaboration Center (ATxCC) in California in 2021. This cutting-edge facility is strategically designed to expedite the development and commercialization processes of cell therapies, reflecting the company's commitment to innovation in biotechnological solutions. Moreover, Thermo Fisher boasts an extensive geographical reach, with an operational presence in over 180 countries across key regions, including North America, Europe, Asia, the Middle East, Africa, and Latin America. This global footprint not only enhances the company’s ability to serve a diverse customer base but also positions it favorably to respond to emerging market needs and trends in the field of molecular testing and biotechnology.

Merck KGaA (Germany): Merck KGaA is a leading global company that specializes in providing innovative health science solutions aimed at advancing healthcare through a comprehensive range of technologies and services. Their offerings encompass the entire lifecycle of health science, spanning from the initial stages of discovery and development to the critical phase of diagnosis. Within the Life Sciences segment, Merck KGaA excels in delivering a diverse array of services tailored to meet the needs of researchers and developers in the field of advanced therapies and biologics. These services include contract testing solutions that ensure rigorous evaluation and validation, raw material testing that guarantees the quality and integrity of components used in production, bulk lot release testing that ascertains the safety and efficacy of larger batches, and final product release testing that confirms that the end products meet all regulatory and safety standards. The company’s robust portfolio of offerings not only underscores its commitment to quality and excellence but also significantly enhances collaboration with clients by providing them with the necessary tools and expertise to drive innovation. Merck KGaA has established a strong position in the market, which can be attributed to its exceptional brand recognition and the trust placed in its extensive experience and scientific knowledge. This combination of factors positions Merck KGaA as a preferred partner for organizations looking to push the boundaries of health science and improve patient outcomes.

Market Ranking

The residual DNA market is highly consolidated, with five major players collectively holding approximately 43–45% of the total market share. Thermo Fisher Scientific Inc. holds a dominant position in the market, driven by its comprehensive portfolio of residual DNA testing solutions, which includes advanced instruments, sophisticated software, robust kits, and integrated services. The company's substantial market share is attributed to its ability to cater to diverse analytical needs across various applications. Merck KGaA, Charles River Laboratories, F. Hoffmann-La Roche Ltd, and Maravai LifeSciences have also secured significant market portions by prioritizing research and development initiatives aimed at launching innovative products that enhance their competitive edge. The burgeoning growth potential in the Asia Pacific and Latin American regions presents strategic opportunities for these companies to expand their operational footprint and capitalize on emerging market trends. Regional & emerging players hold the remaining 55-57% of the market, leading to significant consolidation. Key drivers of market expansion include advancements in technology, innovative product development, strategic collaborations, and a rising demand from the pharmaceutical and biopharmaceutical sectors.

Related Reports:

Residual DNA Testing Market by Product & Service (Consumable, Instrument & Software), Technology (PCR), Test Type (Raw, Final, Bulk Lot Release Testing), Application (mAb, CGT, Vaccine), End User (Pharma & Biotech, CRO & CDMO) - Global Forecast to 2030

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com